Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World data on glofitamab shows promise for Tough-to-Treat lymphoma

NCT ID NCT06994169

Knowledge-focused Sponsor: The Lymphoma Academic Research Organisation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks back at medical records of about 250 adults with large B-cell lymphoma who received the drug Glofitamab through a special access program in France. The goal is to see how well the drug works and what side effects occur in everyday practice, especially in patients whose cancer came back after CAR-T cell therapy. Researchers will track tumor shrinkage and survival over at least 9 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

French patients enrolled in the EAP before 1st of November 2024 and treated with at least Obinutuzumab pretreatment and one infusion of Glofitamab for R/R DLBCL We expect to collect data from 200-250 patients from this population with a minimum of 6 months of follow-up.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * patient enrolled in the French Glofitamab EAP for R/R DLBCL before 2024 November 1st, 2024 * patient who received at least Obinutuzumab pretreatment and one infusion of Glofitamab * adult patient * patient who is informed of the study and who did not oppose to their data collection Exclusion Criteria: * none

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Large B-cell lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

large B-cell lymphoma relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Large B-cell lymphoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    30 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CH Victor Dupouy

    RECRUITING

    Argenteuil, 95100, France

  • CH d'Avignon - Hôpital Henri Dufaut

    RECRUITING

    Avignon, 84000, France

  • CH de Dunkerque

    RECRUITING

    Dunkirk, France

  • CH de Mulhouse Sud Alsace

    RECRUITING

    Mulhouse, 68070, France

  • CH de Quimper Cornouaille

    RECRUITING

    Quimper, 29107, France

  • CH de la Côte Basque

    RECRUITING

    Bayonne, France

  • CHR d'Orléans

    RECRUITING

    Orléans, France

  • CHRU Besançon - Hôpital Minjoz

    RECRUITING

    Besançon, France

  • CHRU de LILLE - Claude Huriez

    RECRUITING

    Lille, France

  • CHRU de Nancy - Hôpital de Brabois

    RECRUITING

    Vandœuvre-lès-Nancy, France

  • CHU Lyon Sud

    RECRUITING

    Pierre-Bénite, France

  • CHU de Dijon - Hôpital le Bocage

    RECRUITING

    Dijon, 21000, France

  • CHU de Grenoble - Hôpital Albert Michallon

    RECRUITING

    La Tronche, France

  • CHU de Poitiers - Hôpital de La Milétrie

    RECRUITING

    Poitiers, France

  • CHU de Rennes - Hôpital de Pontchaillou

    RECRUITING

    Rennes, France

  • CHU de Strasbourg

    RECRUITING

    Strasbourg, France

  • Centre Léon Bérard

    RECRUITING

    Lyon, 69373, France

  • Ch de Bretagne Atlantique

    RECRUITING

    Vannes, France

  • Chu Bretonneau

    RECRUITING

    Tours, France

  • Chu de Bordeaux - Hopital Haut-Leveque

    RECRUITING

    Pessac, France

  • Clinique du Pont de Chaume

    RECRUITING

    Montauban, France

  • Gustave Roussy Cancer Campus Grand Paris

    RECRUITING

    Villejuif, France

  • Hopital D'Instruction Des Armees Percy

    RECRUITING

    Clamart, 92141, France

  • Hopital Henri Mondor

    RECRUITING

    Créteil, France

  • Hopital Saint Vincent-de-Paul

    RECRUITING

    Lille, France

  • Hopital Saint-Louis

    RECRUITING

    Paris, France

  • Hôpital de Libourne

    RECRUITING

    Libourne, France

  • INSTITUT PAOLI CALMETTES - Service Hématologie

    RECRUITING

    Marseille, France

  • Institut Curie - Site Saint-Cloud

    RECRUITING

    Saint-Cloud, France

  • Institut Universitaire du Cancer de Toulouse - Oncopole

    RECRUITING

    Toulouse, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.